Table 1 Baseline demographics and clinical characteristics of patients infected by SARS-CoV-2 and association between these characteristics and mortality.

From: Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Characteristic

Number (proportion) unless specified otherwise

Age, median age in years, (min–max)

57.7 (5.2–72.8)

Male sex

32 (57.1)

CAR T-cell therapy indication

  B-cell acute lymphoblastic leukemia

7 (12.5)

  B-cell non-Hodgkin lymphoma

46 (82.1)

  Multiple myeloma

3 (5.4)

Disease status at time of COVID-19 diagnosis

  Relapse/progression

14 (15)

  Partial response

7 (12.5)

  Complete remission

35 (62.5)

Metabolic comorbidities (obesity, hypertension, diabetes, hypercholesterolemia, smoking, and cardiovascular disease)

  Yes

18 (32.1)

  No

38 (67.9)

Lansky/Karnofsky-score at time of COVID-19 diagnosis

  <70

10 (17.9)

  ≥70

46 (82.1)

Oxygen therapy

  No oxygen support needed,

32 (57.1)

  Oxygen support needed

24 (42.9)

  Invasive mechanical ventilation

16 (28.6)

  Noninvasive ventilation (noninvasive positive pressure ventilation)

2 (3.6)

COVID-19 treatment

  Dexamethasone

10 (17.9)

  (Methyl)prednisolone

2 (3.6)

  Tocilizumab

8 (14.3)

  Baricitinib

2 (3.6)

  Eculizumab

1 (1.8)

  Remdesivir

20 (35.7)

  Lopinavir/Ritonavir

1 (1.8)

  Chloroquine/Hydroxychloroquine

1 (1.8)

  Convalescent plasma

17 (30.4)

  IVIG non-SARS-CoV-2

1 (1.8)

  Anticoagulants (either prophylaxis or treatment)

19 (33.9)

  No treatment

15 (26.8)

Resolution of COVID-19 in surviving patients

  Clinical resolution

10 (17.9)

  Virologic (PCR) resolution

21 (37.5)

  Clinical COVID-19 median duration, days (min–max)

20.0 (0–157)

  Virologic COVID-19 median duration, days (min–max)

48 (6–113)

Factors associated with mortality (HR, 95% CI, P value)

  Age at time of COVID-19

1.39 (1.05–1.86), p = 0.02

  Performance status at time of COVID-19

0.71 (0.56–0.89), p = 0.003

  Metabolic comorbidity

2.75 (1.19–6.35), p = 0.02

  Tumor not in complete remission at time of COVID-19

2.40 (1.04–5.55), p = 0.04

Back to article page